SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech - Technical Analysis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: stockman_scott who wrote (180)3/19/2002 8:20:05 AM
From: JEB  Read Replies (2) of 544
 
INGN has been on my watch list since I first studied the P53 project. A lot of new discoveries came out of that project including a new philosophy of drug trends for the future by the AMA.

Introduction of P53 into the system requires a protein to activate the killer cell activity. To date, the introduction of P53 has given average results so it is more of a gamble to pass FDA muster but it still could.

INGN owns a protein in pre-clinical called BAK that destroyed 99.9999999999999% of the breast cancer cells in cell cultures. This is the one I am following.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News